{"page":{"totalFilteredElements":67},"studies":[{"active":true,"description":"Evaluierung der adjuvanten Therapie beim Dickdarmkrebs im Stadium II nach ctDNA-Bestimmung","eudractNumber":"2018-003691-12","id":5573,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"MSI (Mikrosatelitteninstabilität)","id":"mt_51"},{"name":"MSI-H","id":"mt_52"},{"name":"Mismatch Repair Deficiency (dMMR)","id":"mt_270"}],"nctNumber":"NCT04089631","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2020-08-07T10:52:25+02:00","shortTitle":"Circulate AIO-KRK-0217","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>COLOPREDICT PLUS 2.0 Register</div><div>Retro- und prospektive Erfassung der Rolle von MSI und KRAS f&#252;r die Prognose beim Kolonkarzinom im Stadium I + II + III</div><div><br /></div><div>DRKS00004305 (keine weiteren Registriernummern)</div>","eudractNumber":null,"id":9356,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-08-31T10:12:47+02:00","shortTitle":"ColoPredict Plus 2.0 Register","therapeutical":false,"therapyLines":[{"id":"tl_6","name":"Adjuvant"}]},{"active":true,"description":"<div>COLOPREDICT PLUS 2.0 Register</div><div>Retro- und prospektive Erfassung der Rolle von MSI und KRAS f&#252;r die Prognose beim Kolonkarzinom im Stadium I + II + III</div><div><br /></div><div>DRKS00004305 (keine weiteren Registriernummern)<br /></div>","eudractNumber":null,"id":4652,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2021-06-19T11:08:41+02:00","shortTitle":"ColoPredict Plus 2.0 Register","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>COLOPREDICT PLUS 2.0 Register</div><div>Retro- und prospektive Erfassung der Rolle von MSI und KRAS f&#252;r die Prognose beim Kolonkarzinom im Stadium I + II + III</div><div><br /></div><div>DRKS00004305 (keine weiteren Registriernummern)</div>","eudractNumber":null,"id":3456,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2016-11-15T10:13:22+01:00","shortTitle":"ColoPredict Plus 2.0 Register","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Ein Register f&#252;r Befunde und Videos von Endoskopien in der Gastroenterologie","eudractNumber":null,"id":11473,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06920680","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-07-25T10:02:09+02:00","shortTitle":"ColoReg","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Postoperative Betreuung von Patienten mit tiefem anterioren Resektionssyndrom (LARS) nach operativer Behandlung des Rektumkarzinoms.<div><br /></div><div>DRKS00033615</div>","eudractNumber":null,"id":10726,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-07-01T10:20:30+02:00","shortTitle":"Coloplast/LARS Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"DESTINY-Biliary\nTract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and\nRilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab\nfor First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract\nCancer","eudractNumber":"2023-508057-19-00","id":10413,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06467357","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-04-14T09:21:26+02:00","shortTitle":"DESTINY-BTC 01 D781PC00001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Laparoscopic versus robot-assisted left-sided pancreatectomy for benign and pre-malignant lesions (DIPLOMA-3): an international multicenter patient-blinded randomized controlled trial","eudractNumber":null,"id":11728,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06939023","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2026-03-10T12:09:26+01:00","shortTitle":"DIPLOMA-3","therapeutical":true,"therapyLines":[]},{"active":true,"description":"<u>E</u>ffekt einer <u>c</u>oordinierten <u>H</u>ilfestellung f&#252;r <u>T</u>umorpatienten durch intensivierte Supportivangebote: <u>e</u>ine <u>r</u>andomisierte kontrollierte Studie","eudractNumber":null,"id":2820,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2016-12-16T12:27:26+01:00","shortTitle":"ECHTER-001","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Ergebnisqualit&#228;t bei Darmkrebs: Identifikation von Unterschieden und Ma&#223;nahmen zur fl&#228;chendeckenden Qualit&#228;tsentwicklung","eudractNumber":null,"id":10690,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-01-01T15:53:49+01:00","shortTitle":"EDIUM","therapeutical":false,"therapyLines":[]}]}